LRRK2-PD patients are effectively treated with DBS and Levopoda administration, but the beneficial effect of this symptomatic treatment of motor symptoms is temporally limited and it does not modify the clinical course of the disease. The gene discussed is LRRK2; the disease is Parkinson disease.